Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D62FLA
|
|||
| Drug Name |
BHQ880
|
|||
| Synonyms |
BHQ-880A; Anti-DKK1 monoclonal antibody (multiple myeloma), Novartis
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 2 | [1], [2] | |
| Company |
Novartis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dickkopf-related protein 1 (DKK1) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Wnt signaling pathway | |||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Wnt Signaling Pathway | ||||
| FSH Signaling Pathway | ||||
| Pathway Interaction Database | Presenilin action in Notch and Wnt signaling | |||
| Wnt signaling network | ||||
| Direct p53 effectors | ||||
| Regulation of nuclear beta catenin signaling and target gene transcription | ||||
| Validated targets of C-MYC transcriptional repression | ||||
| Reactome | TCF dependent signaling in response to WNT | |||
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | ||||
| WikiPathways | Mesodermal Commitment Pathway | |||
| Endoderm Differentiation | ||||
| Differentiation Pathway | ||||
| Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
| Primary Focal Segmental Glomerulosclerosis FSGS | ||||
| Cardiac Progenitor Differentiation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01302886) Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009 Jul 9;114(2):371-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.